Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Tumor necrosis factor-weak (TWEAK) and its receptor Fn14 are upregulated in tumors.
• Fn14 expression in tumors is linked to cachexia, a wasting syndrome.

Purpose of the Study:

• To investigate the role of Fn14 signaling in tumor-induced cachexia.
• To evaluate the therapeutic potential of anti-Fn14 antibodies in treating cancer cachexia.

Main Methods:

• Utilized mouse models with tumors expressing Fn14.
• Administered antibodies targeting Fn14.
• Assessed tumor growth, weight loss, inflammation, and muscle/fat mass.
• Compared cachexia development in wild-type versus Fn14- and TWEAK-deficient hosts.

Main Results:

• Anti-Fn14 antibodies significantly extended lifespan by inhibiting tumor-induced weight loss.
• Antibodies reduced tumor-induced inflammation and loss of fat and muscle mass.
• Fn14 signaling within the tumor, not the host, drives cachexia.

Conclusions:

• Fn14 plays a critical role in the etiology of cancer cachexia.
• Anti-Fn14 antibodies represent a promising therapeutic strategy for cachexia.
• Targeting Fn14 may improve quality of life and survival for cancer patients.